Recombinant Factor VIIa Concentrate versus Plasma-derived Concentrates for the Treatment of Acute Bleeding Episodes in Persons with Haemophilia and Inhibitors
Emanuela Marchesini, Domenico Prisco, Alfonso Iorio
Persons with haemophilia (PWH) experience spontaneous or traumarelated bleedings, most commonly joint bleeds, which progressively lead to swelling, limitation of movement, cartilage destruction and haemophilic arthropathy.1 Regular replacement therapy with clotting factor concentrates significantly improves the quality of life in PWH, dramatically reducing the bleeding rate and preserving the joint health status.2,3 The development of […]